NEW YORK, April 7, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Amgen Inc. (NASDAQ: AMGN),
Humana Inc. (NYSE: HUM), Aetna Inc. (NYSE: AET), Perrigo Co. (NYSE: PRGO), and Charles River Laboratories (NYSE: CRL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Amgen Inc.Analyst Notes
On March 31, 2014, Amgen Inc. (Amgen) announced new detailed data from two Phase 3 pivotal studies regarding patients with high cholesterol who cannot tolerate statins (GAUSS-2) and patients undergoing statin therapy with high cholesterol (LAPLACE-2), stating that treatment using novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in significant reduction in low-density lipoprotein cholesterol (LDL-C) between 37-39%, compared with ezetimibe in patients belonging to GAUSS-2 and achieved 55-76% compared to placebo when used in combination with patients belonging to LAPLACE-2. According to Amgen, evolocumab is an investigational fully human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein reducing the liver's ability to remove LDL-C from the blood. For this study, more than 4,000 patients are involved. Sean E. Harper, M.D., Executive Vice President of Research and Development, Amgen, said, "We hope that evolocumab will be able to help patients who are on a moderate or high-intensity statin and not adequately controlled, as well as patients who cannot tolerate statins and are in need of an alternate treatment option to help lower their LDL cholesterol levels." The full analyst notes on Amgen Inc. will be available to download free of charge at:
http://www.AnalystsReview.com/04072014/AMGN/report.pdf
Humana Inc. Analyst Notes
On March 31, 2014, Humana Inc. (Humana) announced the appointment of Brian A. Kane as Senior Vice President and CFO effective June 2014. According to the Company, Kane will report directly to President and CEO Bruce Broussard and serve on Humana Management Team, which sets the strategic direction for the Company. Prior to joining Humana, Kane was the Managing Director at Goldman, Sachs & Co. for 17 years, handling client relationships as well as leading strategic and financing transactions for companies in multiple industries. The Company informed that his immense background in health and insurance, plus consumer retail propelled him to his current position. Commenting on the appointment, Broussard said, "I am excited to have Brian joining our leadership team," Broussard said. "He brings financial and strategic breadth that will nicely complement the operational depth of Steve McCulley." The full analyst notes on Humana Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04072014/HUM/report.pdf
Aetna Inc. Analyst Notes
On March 24, 2014, Aetna Inc. (Aetna) announced that it will release its Q1 2014 financial results on April 24, 2014, at 6:00 a.m. ET. The Company will also host a conference call beginning 8:30 a.m. ET that same day. Other information related to the release will be made available on Aetna website. The full analyst notes on Aetna Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04072014/AET/report.pdf
Perrigo Co.Analyst Notes
On April 1, 2014, Perrigo Co. (Perrigo) announced that it has initiated a market launch and made its first shipments of the authorized generic version of LEO Pharma A/S' Taclonex Ointment. The product, which is designed to treat plaque psoriasis of the scalp and body in adult patients, reached an approximate $110 million brand sales over the year. Commenting on the brand sale figures, Joseph C. Papa, Chairman, President and CEO, Perrigo, said, "This product was the result of the continued hard work and dedication of our Perrigo Rx team. This launch is another example of Perrigo's investment and commitment to making quality healthcare more affordable for consumers." The full analyst notes on Perrigo Co. are available to download free of charge at:
http://www.AnalystsReview.com/04072014/PRGO/report.pdf
Charles River Laboratories Analyst Notes
On March 31, 2014, Charles River Laboratories (Charles River) announced its acquisition of the CRO services division of Galapagos NV, including both Argenta and BioFocus, positioning the Company as a full service, early-stage contract research organization with integrated in vitro and in vivo capabilities. According to the Company, the purchase price of €129 million cash is subject to certain post-closing working capital adjustments, plus future performance payments of up to €5 million. In addition, the acquisition is expected to add approximately 6% to Charles River's net sales in 2014, and also be accretive to non-GAAP EPS by $0.10. The full analyst notes on Charles River Laboratories are available to download free of charge at:
http://www.AnalystsReview.com/04072014/CRL/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
